KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Gains from Investment Securities: 2009-2024

Historic Gains from Investment Securities for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $77.6 million.

  • Biomarin Pharmaceutical's Gains from Investment Securities fell 63.19% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.2 million, marking a year-over-year decrease of 24.03%. This contributed to the annual value of $77.6 million for FY2024, which is 1.63% up from last year.
  • As of FY2024, Biomarin Pharmaceutical's Gains from Investment Securities stood at $77.6 million, which was up 1.63% from $76.3 million recorded in FY2023.
  • In the past 5 years, Biomarin Pharmaceutical's Gains from Investment Securities ranged from a high of $77.6 million in FY2024 and a low of $45.8 million during FY2021.
  • For the 3-year period, Biomarin Pharmaceutical's Gains from Investment Securities averaged around $69.4 million, with its median value being $76.3 million (2023).
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first decreased by 13.28% in 2021, then spiked by 40.59% in 2023.
  • Yearly analysis of 5 years shows Biomarin Pharmaceutical's Gains from Investment Securities stood at $52.8 million in 2020, then decreased by 13.28% to $45.8 million in 2021, then rose by 18.51% to $54.3 million in 2022, then surged by 40.59% to $76.3 million in 2023, then increased by 1.63% to $77.6 million in 2024.